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Abstract
To penetrate susceptible cells, HIV-1 sequentially interacts with two highly conserved cellular receptors, CD4 and a
chemokine receptor like CCR5 or CXCR4. Monoclonal antibodies (MAbs) directed against such receptors are currently under
clinical investigation as potential preventive or therapeutic agents. We immunized Balb/c mice with molecular complexes of
the native, trimeric HIV-1 envelope (Env) bound to a soluble form of the human CD4 receptor. Sera from immunized mice
were found to contain gp120-CD4 complex-enhanced antibodies and showed broad-spectrum HIV-1-inhibitory activity. A
proportion of MAbs derived from these mice preferentially recognized complex-enhanced epitopes. In particular, a CD4-
specific MAb designated DB81 (IgG1K) was found to preferentially bind to a complex-enhanced epitope on the D2 domain
of human CD4. MAb DB81 also recognized chimpanzee CD4, but not baboon or macaque CD4, which exhibit sequence
divergence in the D2 domain. Functionally, MAb DB81 displayed broad HIV-1-inhibitory activity, but it did not exert
suppressive effects on T-cell activation in vitro. The variable regions of the heavy and light chains of MAb DB81 were
sequenced. Due to its broad-spectrum anti-HIV-1 activity and lack of immunosuppressive effects, a humanized derivative of
MAb DB81 could provide a useful complement to current preventive or therapeutic strategies against HIV-1.
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Introduction
The CD4 protein expressed on the membrane of T lymphocytes
and mononuclear phagocytic cells serves as the primary HIV-1
receptor, which mediates binding of the viral envelope (Env) to the
cellular membrane. Additional receptor molecules such as the
chemokine receptors CCR5 and CXCR4 function as obligatory
coreceptors for HIV-1 entry [1,2,3]. Binding of Env to CD4
initiates a chain of events, including major conformational changes
in the external Env glycoprotein gp120 that reshuffle its fine
antigenic structure[4]. This process leads to the unraveling or de
novo formation of specific epitopes, which are critically involved in
subsequent interactions with the coreceptors [5], culminating in
the exposure of the hydrophobic fusion domain of the transmem-
brane envelope subunit, gp41. Fusion of the apposed cellular and
viral membranes ensues [5]. Antibodies that block HIV-1 Env-
mediated fusion typically interfere with the binding of CD4 with
gp120, but several neutralizing antibodies that interfere with post-
binding events have also been described [5,6,7,8]. In particular,
antibodies directed towards determinants positioned far from
the receptor-binding site have been identified in sera from gp
120-immunized animals [9,10], in patient sera with strong
neutralizing activity, and in antibody libraries obtained from
HIV-1-seropositive individuals [6,11,12]. This property is not
exclusive to HIV-1, as it was also reported for antibodies elicited
by herpes simplex virus and Epstein-Barr virus [13,14].
Besides Env-specific antibodies, CD4-targeted antibodies may
also be involved in HIV-1 inhibition both at the binding and post-
binding levels. We previously identified anti-CD4 antibodies in
both European [15] and Asian [16] HIV-1-seronegative individ-
uals who were apparently protected from infection despite
repeated exposure to HIV-1 through an infected sexual partner.
These antibodies included binding to epitopes exposed on the
receptor-Env complex that were correlated with in vitro inhibition
of HIV-1-induced cell fusion [16]. In all of these circumstances, it
appears that antibodies that recognize determinants that partic-
ipate in post-binding steps can interrupt the chain of events
leading to HIV-1 entry into the cell.
Despite worldwide efforts, attempts to develop a protective anti-
HIV vaccine have been thus far unsuccessful [17]. Several reasons
may underlie this failure, including the elusive antigenic make up
of the HIV-1 Env, which is extremely efficient in escaping
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immunity in the case of a chromosomally-integrating retrovirus,
which is beyond the reach of conventional vaccines [18]. A
promising strategy for the induction of broadly reactive antibodies
is based on the use of immunogens presenting non-polymorphic
epitopes that are expressed on the HIV-1 entry complex, i.e., the
Env-receptor complex. Immunization with a single-chain chimeric
molecule encompassing HIV-1 gp120 bound to a truncated form
of human CD4 has yielded some degree of protection in a macaque
model [19]. It is worth noting that the focus in these attempts
was restricted to epitopes expressed on the HIV-1 component.
However,ithasbeenshownthatinvariantepitopesexpressedonthe
receptor and coreceptor may also be effectively targeted by
neutralizing antibodies. Indeed, a non-immunosuppressive anti-
CD4 monoclonal antibody (MAb) that does not interfere with
gp120 binding [20] and a CCR5-specific MAb (PRO-140) [21] are
currently under clinical investigation as potential therapeutic or
preventive treatments. The non-polymorphic nature of these
cellular antigens makes these approaches worth of further inves-
tigation also in the framework of active immunization protocols.
In this study, we used a novel immunization approach based on
fusion-competent native Env-CD4 molecular complexes in a
mouse model with the aim of eliciting broadly reactive neutralizing
antibodies. We describe herein the specificity and function of a
MAb, designated DB81, that recognizes a complex-enhanced
epitope on human CD4. This MAb inhibits cell fusion and viral
replication by divergent HIV-1 strains by a post-binding me-
chanism and exerts little, if any, suppressive effects on T-cell
activation in vitro, thereby providing a potentially useful comple-
ment to current anti-HIV-1 strategies.
Materials and Methods
Cells
NIH 3T3, HeLa, Sup-T1 and RK13 cells were obtained from
the American Type Culture Collection. The PM1 cell clone has
been described elsewhere [22] and is available from the AIDS
Research and Reference Reagent Program (Rockville, MD). All
cell lines were maintained at 37uC in a 5% CO2 atmosphere and
grown in RPMI 1640 medium (Gibco, Invitrogen Life Technol-
ogies, Milan, Italy) supplemented with 10% heat-inactivated fetal
bovine serum (FBS, Hyclone, Logan, UT, USA), 2 mM L-
glutamine and antibiotics (Gibco); this medium will be hereafter
referred to as complete medium. The 8- azaguanine resistant, non-
secreting P3X63Ag8.653 mouse myeloma (American Type Cul-
ture Collection, Manassas, VA, USA) was maintained in RPMI
1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L
sodiumbicarbonate,4.5 g/Lglucose,10mMHEPES,and 1.0 mM
sodium pyruvate, 90%; fetal bovine serum, 10%. P3X63
Ag8.653 was used as fusion partner for producing hybridomas.
Expression of Env by recombinant vaccinia vectors
Vaccinia virus was used as a vector to express HIV-1 Ba-L Env
on NIH 3T3 effector cells [23]. The vCB-43, HIV-1 Ba-L Env
[24], derived from the WR parental strain, was used for this
purpose. Target cells used for the functional evaluation of fusion
competence of soluble CD4-activated immunogens [25] were
induced to express the CCR5 coreceptor using plasmid pGA9-
CKR5 [26]. Env-mediated cell fusion was quantified with a
previously described vaccinia virus-based reporter gene assay [27].
Proteins, peptides and antibodies
The following recombinant proteins were provided by NIH AIDS
Research and Reagent program, Rockville, (MD): two-domain (2D)
soluble CD4 (amino acids 1 to 183, produced in E. coli); 4-domain
(4D) soluble CD4 (amino acids 1 to 369, produced in CHO cells),
human MAb 17b, recombinant HIV-1 IIIB gp120 and recombi-
nant HIV-1 Ba-L gp120. RANTES (Regulated on Activation,
Normal T-cell Expressed and Secreted) was purchased from R&D
Systems (Minneapolis, MN, USA). The Leu3a mouse MAb anti-
human CD4, specific to the gp120-binding site, was purchased from
Becton-Dickinson Biosciences (Milan, Italy). Rabbit ATG (thymo-
globulin) was obtained from Imtix Sangstat (Milan, Italy). Rabbit
complement was obtained from One Lambda Inc. (Canoga park
CA,USA). Phytoemoagglutinin (PHA) was from Sigma Italia
(Milan, Italy) and tetanus toxoid from Connaught Laboratories
Inc. (Toronto, Canada). The Full-Length Single Chain (FLSC)
construct consisting of full-length HIV-1Ba-L gp120 and the D1D2
domains of CD4 joined by a 20-amino-acid linker [28] was kindly
provided by Dr. A. De Vico. Two 19-mer syntethic peptides
(GTWTCTVLQNQKKVEFKID and GTWTCTVSQDQKTV-
EFKID) were synthesized by solid-phase F-moc using an Applied
Biosystems 433A peptide synthesizer (Foster City, CA) and were
purified by semi-preparative Reverse Phase-High Performance
Liquid Chromatography (RP-HPLC). Linear gradients of acetoni-
trile in water/0.1% trifluoroacetic acid were used to elute the bound
peptides. The purity of the peptides (over 95%) was confirmed by
analytical RP-HPLC, and their mass was determined by matrix-
assisted laser desorption/ionization time-of-flight analysis with a
Voyager-RP Biospectrometry Workstation (PE Biosystem, Inc.).
Observed experimental mass values were in agreement with the
theoretical calculated ones. The 27-amino acid CD4M3 mini-
protein, which was designed on the basis of structural similarity
between the CDR2-like loop of the first CD4 domain and the beta-
hairpin region of scyllatoxin[29] was a generous gift from the late
C. Vita.
Preparation and validation of the immunogens
NIH 3T3 cells were infected with gp160-expressing [24] recom-
binant vaccinia viruses overnight at 32uC to induce expression of
the recombinant proteins. The following day, if appropriate, the
cells were treated with 2D-CD4 (20 mg per million cells) for
30 min. on ice and subsequently washed twice with PBS to remove
unbound soluble CD4. The cells used for immunization were fixed
with paraformaldehyde for 10 min at room temperature at a cell
density of 1610
6 cells per ml, washed twice in PBS and checked by
flow cytometry for the expression of a CD4-induced epitope, 17b,
before injection. The 17b MAb is directed to the coreceptor-
binding domain of gp120 and only faintly reacts with Env-
expressing cells in the absence of soluble CD4 [30]. Only the
preparations of immunogens displaying a CD4-dependent in-
crease of 17b binding to Ba-L gp120 expressed by vCB43 infected
NIH 3T3 cells after fixation were considered suitable as im-
munogens for inoculation. A functional quality control was also
performed, aimed at verifying the competence for fusion of CD4-
activated immunogens. In this case, the effector cell population
were infected with vaccinia virus expressing bacteriophage T7
RNA polymerase encoded by the vP11T7gene 1 [31], and the
target cell population with a vaccinia virus expressing the lacZ
reporter gene under the control of the T7 promoter (plasmid
pG1NT7-gal, R. A. Morgan, National Human Genome Research
Institute). Additionally, target cells were transfected with a plasmid
expressing the CCR5 coreceptor (GA9-CKR5) [26] or the
CXCR4 coreceptor as a control (pYF1-fusin) [32]. Effector and
target cells were mixed in duplicate wells of 96-well plates (2610
5
cells of each type per well). As negative controls, the cells
were incubated with buffer alone. Plates were incubated for
2.5 h at 37uC, and fusion was quantified by measurement of
CD4-gp120 Complex Specific Anti-HIV-1 Antibodies
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a 96-well spectrophotometer (Titertek, Huntsville, Alabama, USA).
Animals and immunization protocol
Four to 5 weeks old female Balb/c mice bred by Charles River
(Calco, Italy) were used for immunizations, which were performed
in a standard-pathogen-free animal facility. Four mice per each
experimental condition were used. Subcutaneous injections were
made in the dorsal part of the neck. A total of 5610
5 cells in
250 ml of PBS were used per inoculation. A total of 4 inoculations
were made at 20- to 25-day intervals, and blood was drawn from
the tail vein 10–14 days after the last recall injection. All animal
work have been conducted according to national and international
guidelines. In particular, animals were maintained in standard
pathogen free conditions, and every care was taken to minimize
the suffering related to experimental work and to ameliorate their
living conditions. The study was approved by the Institutional
Ethic on Animal Welfare (IACUC) of the San Raffaele Scientific
Institute. Namely, the following approvals were obtained, fol-
lowing formal applications: record number 397, July 7th, 2009;
record number 222, November 17, 2003; record number 141,
March 29, 2001.
Immunochemistry
ELISA reagents were obtained from Sigma (Milan, Italy), unless
differently specified. Binding activity to solid-phase antigens was
measured as follows: recombinant molecules were used for coating
ELISA plates (Costar, Milan, Italy), diluted in PBS and incubated
at 4uC overnight. Recombinant 2D-CD4 (molecular weight:
20,14) was used at 2 mg/ml for coating. CD4-gp120 complexes
were formed by pre-incubation of equimolar amounts of the two
moieties in ice for 20 min. All subsequent incubations, except for
developing, were for 1 h at 20uC; PBS containing 0,05% Tween
20 was used for washing.
Aliquotes of phosphatase-conjugated gp120 were prepared by
Lightning Link Alkaline Phosphatase Conjugation Kit Protocol,
according to Manufacturer instructions (Novus Biologicals, Cam-
bridge, UK). Blocking of ELISA wells was done with 1% bovine
serum albumin (BSA, Sigma) in PBS. Supernatants of hybridomas
were tested in triplicate at different dilutions in PBS containing
0.05% Tween 20. Purified antibodies were tested over the indi-
cated dilution ranges. Binding of IgG antibodies was revealed with
an affinity-purified, phosphatase-conjugated polyclonal antibody
to mouse IgG (Southern Biotech, Birmingham, AL, USA). The
reaction was developed with PNPP-developing reagent and read
with an automated plate reader by using a 405 nm filter (Titertek,
Pharmacia, Uppsala, Sweden). To test inhibition of gp120 binding
to solid-phase CD4, after coating the plates with 5 mg/ml rCD4,
50 ml of phosphatase-labeled gp120 (5 mg/ml) was added and
incubated for 1 h, plus or minus serial twofold dilutions of the test
antiserum. The phosphatase activity was then measured by the
rate of PNPP hydrolysis. The inhibition caused by the test anti-
body was expressed as percent decrease from the binding of
untreated control gp120.
Production of monoclonal antibodies
A conventional protocol for the generation of MAbs from cell
hybrids between spleen cells of immunized animals and the
P3X63Ag8.653 non-secreting mouse myeloma was used [33].
Antibody purification from cell supernatants was performed by
affinity gel with protein-G-coupled sepharose (Pharmacia) accord-
ing to manufacturer’s instructions. Absorption of MAb DB81
(20 nM in 150 ml of PBS) on solid-phase antigens was done on
wells coated with antigens and blocked with BSA under the same
conditions used in the ELISA assays; 200 microliters of 20 nM
MAb solution were transferred from one well to the following in
ten sequential steps, with 2 min incubation at 20uC before each
step. Uncoated, BSA-blocked wells were used in parallel as controls.
Flow cytometry
Cells used for flow cytometric analysis (500,000 cells per sample)
were incubated for 20 min. on ice with 1 mg of the appropriate
MAb, and binding was revealed with a secondary fluorescein-
conjugated, affinity-purified polyclonal antibody to mouse IgG
used at 0.2 mg per sample (Sigma). A FACScan cytometer equipped
withaCellQuestsoftware(BectonDickinson)wasusedforacquiring
and analyzing the stained samples.
Viruses and preparation of chronically infected cell lines
The laboratory-passaged isolates IIIB and Ba-L were obtained
from the NIH AIDS Research and Reference Reagent Program,
NIAID, NIH (Rockville, MD). The HIV-1 primary isolate B117
was kindly provided by Eva M. Fenyo (Lund University, Sweden),
whereas the 6195 isolate was obtained from the NIBSC-MRC
AIDS Reagent Project (London, UK) within the framework of the
WHO-UNAIDS Network for the Characterization of GloBa-Lly
Prevalent HIV-1 Strains in Relation to Vaccine Development. All
HIV-1 isolates were expanded and titrated in activated primary
human peripheral blood mononuclear cells (PBMC), as previously
reported [34]. Primary isolates were minimally passaged in vitro.
The PM1 cell clone and its persistent infection with biologically
diverse HIV-1 strains have been described elsewhere [22].
Chronically infected PM1 cell lines were obtained for the B117
and the 6195 HIV-1 isolates, whereas for IIIB and MN isolates,
chronically infected SupT1 cell lines were derived. To produce the
chronically infected cell lines, cells were exposed to the viral stocks
at the approximate multiplicity of infection of 0.1, and
subsequently cultured in complete culture medium and monitored
daily for cytopathic effects and extracellular p24 antigen release by
ELISA using commercial antibodies (Aalto Bio Reagents, Dublin,
Ireland). At the peak of the cytopathic effects (typically, day 7-10
post-infection), cells were pelleted, washed once in pre-warmed
complete medium and cultured at low cellular density (5 x 104
cells/ml) with daily replacement of half of the culture medium in
the presence of conditioned supernatants (20% vol/vol) from
uninfected PM1 (or SupT1). In most cases, this treatment resulted
in the appearance, within 10 to 14 days, of small clusters of
healthy-appearing cells that rapidly re-colonized the cultures.
These outgrowing cell lines were chronically infected, as assessed
by the stable expression of cell surface viral envelope and by the
sustained release of extra-cellular p24 antigen.
HIV-1 envelope-mediated fusion assay
An HIV-1 Env-mediated fusion assay was used to evaluate
HIV-1 inhibition. The assay was performed using a modification
of the test, based on vaccinia technology, which was originally
developed by E. Berger and coworkers [27]. In the modified assay,
the effector cells were chronically infected PM1 or SupT1 cells,
whereas the target cells were NIH 3T3 mouse fibroblast cells
permanently expressing human CCR5 or CXCR4, along with
human CD4. Twelve hours before the test, effector cells were
infected with a vaccinia vector expressing bacteriophage T7 RNA
polymerase encoded by vP11T7gene 1 [31], while target cells were
infected with a vaccinia vector expressing the lacZ reporter gene
under the control of the T7 promoter, as described (plasmid
pG1NT7-gal, R. A. Morgan, National Human Genome Research
Institute, personal communication). All vaccinia virus infection
were performed in DMEM medium supplemented with 2.5%
CD4-gp120 Complex Specific Anti-HIV-1 Antibodies
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effector cells were mixed for 2 hrs with the target cells in the
presence or absence of the inhibitors.
T-cell proliferation assays
PBMC were isolated from heparin-treated venous blood drawn
from tetanus toxoid vaccinated healthy lab workers according to
standard protocols based on gradient density (Ficoll Hypaque,
Pharmacia, Uppsala, Sweden). Cells were incubated in 96-well, flat-
bottom plates (PBI International, Milan, Italy) at 37uC in 5% CO2
atmosphere, at a concentration of one million cells per ml in
200 ml in complete medium. Tetanus toxoid (5 mg/ml) (Connaught
Laboratories, Inc, Toronto, Canada) or phytoemoagglutinin (PHA)
(10 mg/ml) were added at time 0. Where appropriated, Leu 3a or
DB81 MAb (5 mg/ml) was also added from the beginning of the
culture. As negative controls, microcultures with medium only were
included. 3H-TdR thymidine (DuPont-NEN, Boston, MA) was
added (1 mCi per well) in the last 18 hrs of a 3- or 5-days culture
time (for PHA- and tetanus toxoid-pulsed cells, respectively). As
read-out of proliferation, cells were harvested (Skatron Instruments,
Lier,Norway) and thymidineincorporationwasmeasured ina beta-
counter (Perkin- Elmer, Shelton, CT, USA).
Complement fixation
PBMC from healthy lab workers (100,000 per test, in RPMI
medium) were reacted (30 min, 37uC) with freshly reconstituted
rabbit complement (Harlan Sera Lab, Loughborough, England),
according to manufacturer’s instruction. As positive control, an
incubation (30 min, 37uC) with anti-human thymoglobuline
(ATG, Imtix-Sangstat s.r.l., samples 20 nM DB81 or Leu 3a
MAb were added, respectively (30 min, 37uC) before complement
addition. Washing steps with PBS were included between in-
cubations, as appropriated. The proportion of necrotic cells was
evaluated by flow cytometry as propidium iodide staining.
Surface plasmon resonance
Binding experiments were performed using a Biacore 2000
equipped with research-grade CM5 sensor chips (Biacore AB,
Uppsala, Sweden). A standard amine-coupling protocol, with N-
hydroxysuccinimide (NHS), 1-Ethyl-3-(3-dimethylaminopropyl)-car-
bodiimide (EDC) and Ethanolamine hydrochloride (pH 8.5) was
used to immobilize the antibody. The immobilization was carried
o u ta tac o n c e n t r a t i o no f4 0n g / ml using 10 mM Hepes Buffer
pH 7.4, 150 mM NaCl (HSP) containing 0.005% P-20 surfactant
(HBS-P) as the running buffer. Flow cell 1 was used as a reference
cell. 2D-CD4 previously incubated with gp120 IIIB protein for 1h
RT was injected at a flow rate of 30 ml/min for 3 minutes. Sample
dilutions were prepared in HBS buffer and binding analyses were
performed at a concentration of 200 nM. Kinetics analyses were
performed at concentrations ranging from 6.25 to 200 nM.
Cloning of the MAb DB81 gene
The V genes of mouse MAb DB81 were reverse transcribed
and amplified using PCR essentially as described [35]. The
variable domains of the antibody were sequenced. Sequencing
reactions were performed on amplification products using the
ABI PRISM Big Dye Terminator Cycle Sequencing kit v1.1
(Applied Biosystems) and examined on an ABI PRSM 3100
Genetic Analyzer (Applied Biosystems), using the DNA Sequenc-
ing Analysis software 3.7 (Applied Biosystems). The following
primers were used for the amplification and sequence: V-
Light: 59 primer GACATTGTGATGACCCAGTTTGC; 39
primer TTTGATTTCCAGCTTGGTGCC V-Heavy: 59 primer
GARGTCCAGCTGCAACAGTCYGGAC; 39 primer TGCA-
GAGACAGTGACCAGAG.
Statistical analysis
Descriptive statistics were used to describe quantitatively the
distribution of collected data. Results are shown as mean values 6
standard error of the mean.
Sequence accession numbers
GenBank CAQ16367.1
Anti-human CD4-HIV-1-gp120 complex DB81 monoclonal
antibody immunoglobulin heavy chain [Mus musculus]
GenBank CAQ16368.1
Anti-human CD4-HIV-1-gp120 complex DB81 monoclonal
antibody immunoglobulin kappa chain [Mus musculus]
Results
NIH-3T3 cells expressing soluble CD4-complexed HIV-1
Env elicit an antibody response to complex-specific
epitopes
Balb/c mice were immunized with autologous NIH-3T3 cells
infected for 24 hours with a recombinant vaccinia virus (vCB-43)
encoding the complete HIV-1 Env gp160 gene cloned from an R5
viral isolate (Ba-L), treated with 2D-CD4 (20 mg/10
6 cells) for 30
minutes and fixed with paraformaldehyde before injection.
Control mice were immunized with cells infected with vCB43
but not treated with soluble CD4. Sera obtained from immunized
mice were screened for IgG binding activities to solid-phase CD4,
gp120 or equimolar CD4-gp120 complexes by ELISA. In all cases,
animals immunized with Env/CD4 complexes developed higher
IgG binding activities to the CD4-gp120 complex than to either
CD4 or gp120 tested separately (Fig. 1A). Of note, this increased
binding activity to the CD4-gp120 complex was not dependent on
the HIV-1 strain from which gp120 was derived, as similar data
were obtained with complexes formed with HIV-1 Ba-L (R5),
HIV-1 IIIB (X4) and HIV-1 JRFL (R5) gp120 (Fig. 1A, 1B and
1C). In sera from control mice injected with NIH-3T3 expressing
uncomplexed Env (i.e., without addition of 2D-CD4), the IgG
binding activities to gp120 and CD4-gp120 complexes were
comparable (Fig. 1D).
HIV-1-neutralizing activity and fine specificity of sera
from immunized mice
Pooled sera derived from mice injected with autologous NIH-
3T3 cells expressing the HIV-1 Ba-L Env in complex or not with
2D-CD4 were tested for inhibition of HIV-1 Env-mediated fusion
using PM-1 of Sup-T1 cells chronically infected with HIV-1 Ba-L
or IIIB, respectively, as effector cells. As shown in Figure 2, sera
obtained from mice immunized with sCD4-complexed Env dis-
played in both cases a stronger fusion-inhibitory activity compared
to those obtained from mice immunized with uncomplexed Env.
The spectrum of binding and neutralizing activity of sera derived
from mice immunized with sCD4-complexed Env will have to be
established with systematic studies on a wide range of genetically
diverse HIV-1 strains.
Sera from immunized mice were then tested in ELISA for their
binding activity to HIV-1 gp120 and for their ability to block the
binding of soluble gp120 to solid-phase CD4. Figures 3A and 3B
show that sera obtained from mice immunized with sCD4-
complexed Env displayed a higher binding activity for gp120 but a
lower ability to interfere with sCD4-gp120 binding, compared to
sera from mice immunized with uncomplexed Env. This result is
CD4-gp120 Complex Specific Anti-HIV-1 Antibodies
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interface on the molecular complexes. Taken together, the results
shown in Figures 2 and 3 suggest that immunization with sCD4-
complexed Env elicited the production of antibodies lacking the
ability to interfere with CD4-gp120 interaction in spite of their
HIV-1-inhibitory activity.
Characterization of hybridomas derived from mice
immunized with NIH-3T3 cells expressing sCD4-complexed
HIV-1 Env
Culture supernatants from hybridomas derived from mice
immunized with NIH-3T3 cells expressing sCD4-complexed
HIV-1 Env were tested for their IgG binding activity against
different molecular targets. The hybridomas were negatively
selected for production of IgG binding to uninfected NIH-3T3
cells and positively selected for production of IgG binding to either
2D-CD4, gp120 (Ba-L) or the 2D-CD4-gp120 (Ba-L) complex. A
total of 25 hybridomas producing MAbs directed against either
gp120 or 2D-CD4 were obtained (Table 1). Eight of these 25
MAbs displayed a higher binding activity against the CD4/gp120
complex than against the uncomplexed molecules. Surprisingly,
however, unlike several MAbs described in the literature that are
directed against CD4-induced epitopes in gp120 [11,36,37], all the
MAbs derived from our mice with complex-enhanced binding
activity were reactive with the CD4 moiety of the complex
(Table 1).
Characterization of MAb DB81
To investigate the epitope specificity of the anti-CD4 MAbs
with complex-enhanced binding activity, a hybridoma that
exhibited preferential recognition of the CD4-gp120 complex
(C9, IgG1k; Table 1) was selected for further studies. The stable
antibody-producing hybridoma was sub-cloned at 0.2 cells per well
and a single clone (DB81) was selected and expanded. Flow
cytometric analysis showed that MAb DB81 recognizes mem-
brane-expressed CD4 on uninfected PM-1 cells, as well as 2D-
2CD4 bound to oligomeric Ba-L gp160 expressed by a
recombinant vaccinia virus in RK13 cells (Fig. 4A). In contrast,
no binding was observed to the complex formed by the Ba-L Env
bound to a CD4 miniprotein, CD4-M3 (Fig. 4B), which contains
only the core residues of the gp120-binding region of CD4 but is
fully capable of inducing CD4-like conformational changes in
gp120. This result further supports the notion that the DB81
epitope maps exclusively to the CD4 molecule and does not
involve gp120.
In agreement with the ELISA data, an increased binding
activity of MAb DB81 was observed when uninfected PM-1 cells
were treated with soluble gp120 derived from either isolate IIIB
(Fig. 4C) or isolate Ba-L (Fig. 4D), further demonstrating that the
DB81 epitope is not involved in the gp120-binding interface and is
better exposed following interaction with gp120. No binding
competition was observed with a panel of anti-CD4 MAbs,
including MAb 55, OKT4, OKT4A, Leu3a, SIM-1 and SIM-4, as
Figure 1. Detection of IgG anti-CD4 and anti-CD4-gp120 complexes in sera from mice immunized with CD4-complexed HIV-1 Env.
he binding activity of IgG present in pooled sera obtained from mice immunized with NIH-3T3 cells expressing HIV-1 Env from various viral isolates
bound to soluble CD4 (A,B,C) or from control mice immunized with cells expressing unbound HIV-1 Env (D) was tested by ELISA. The solid phase
antigens used were recombinant HIV-1 gp120 complexed with equimolar concentrations of 2D-CD4, recombinant gp120 alone or 2D-CD4 alone. The
binding activity was measured not only to Ba-L gp120 (1A and 1D), which is homologous to that used for immunization, but also to gp120 derived
from heterologous viral isolates, JR-FL (Figure 1B) and IIIB (1C).
doi:10.1371/journal.pone.0022081.g001
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shown). Likewise, binding of MAb DB81 to solid-phase human
2D-CD4 and 4D-CD4 was increased by pre-incubation of the
molecule with recombinant gp120 from either the Ba-L or IIIB
strain (not shown). These data demonstrate that MAb DB81 is
directed against a previously unrecognized gp120-induced CD4
epitope.
Reactivity of MAb DB81 with CD4 from nonhuman
primates and preliminary mapping of the DB81 epitope
As a first step toward a precise delineation of the DB81 epitope,
we tested the reactivity of MAb DB81 against peripheral blood T
cells derived from several nonhuman primate species, whose CD4
presents distinct, albeit limited, amino acid sequence diversity. As
indicated in Table 2, MAb DB81 was reactive with T cells derived
from humans and chimpanzees (Pan troglodytes), but not derived
from baboons (Papio anubis) or from three species of macaques
(Macaca mulatta, fascicularis and nemestrina). Sequence alignment of
the CD4 protein from the 6 species examined revealed a surface-
exposed loop region (aa. 184-196) in the second Ig-like C2-type 1
domain containing two nonconservative amino acid substitutions
that clearly segregated with MAb DB81 reactivity (Table 2). To
evaluate the role of this region in MAb DB81 reactivity, we
synthesized two 19mer peptides containing either the human/
chimpanzee sequence (L187, K192) or the baboon/macaque
sequence (S187, T192), and tested their reactivity with MAb DB81
in ELISA. As shown in Figure 5, surface plasmon resonance
clearly demonstrated that MAb DB81 was reactive with the
human CD4-derived peptide but failed to react with the baboon/
macaque- CD4-derived peptide, strongly suggesting that this
region contains the epitope recognized by the MAb. Analysis of
the published tridimensional structures of human CD4 in the
unliganded and gp120-bound state revealed small but significant
conformational differences in the putative DB81 epitope (Figure S1).
Binding kinetics of MAb DB81 to CD4 or CD4-gp120
complexes
By surface plasmon resonance, we measured the specificity and
kinetic rates of binding and dissociation of MAb DB81 to either
sCD4, gp120, the sCD4-gp120 complex, or a previously described
chimeric single-chain molecule, designated FLSC, encompassing
full-length HIV-1Ba-L gp120 and the D1D2 domains of CD4
joined by a 20-amino-acid linker. Figure 6 depicts the sensogram
of these interactions, which were measured with MAb DB81
bound to the solid-phase chip. Binding of MAb DB81 to 2D-CD4
was clearly increased when CD4 was complexed with gp120 from
isolate IIIB (45 versus 16 resonance units), confirming the results
obtained by ELISA (Figure S2). When gp120 from isolate Ba-L
was used, a lower increase was observed (not shown). The chimeric
FLSC peptide was also recognized but showed a much slower
slope of association with MAb DB81 compared to the CD4-gp120
complex. In contrast, no binding was measured with gp120 alone
either from isolate IIIB (Figure 5) or from isolate Ba-L (not shown).
Figure 2. Inhibition of HIV-1 Env-mediated fusion by sera from
mice immunized with CD4-complexed HIV-1 Env. era from mice
immunized with autologous NIH 3T3 cells expressing HIV-1 Ba-L Env in
complex or not with soluble CD4 were tested for inhibition of HIV-1
Env-mediated fusion using PM-1 (A) of Sup-T1 (B) cells chronically
infected with HIV-1 Ba-L or IIIB, respectively, as effector cells. NIH 3T3
cells expressing human CD4 and the appropriate coreceptor (CXCR4 or
CCR5) were used as target cells. Sera from 4 immunized mice were
pooled. Fusion inhibition is expressed as percent of the positive control,
i.e., the amount of fusion measured when the fusion partners were
reacted in the presence of pre-immune sera.
doi:10.1371/journal.pone.0022081.g002
Figure 3. Biological effects of sera derived from mice
immunized with CD4-complexed HIV-1 Env. A. Binding of pooled
sera derived from mice immunized with HIV-1 Env in complex or not
with soluble CD4 to solid phase gp120 (from isolate HIV-1 Ba-L). B.
Inhibition of phosphatase-labeled Ba-L gp120 binding to solid-phase
2D-sCD4 by sera from mice immunized with HIV-1 Env in complex or
not with soluble CD4. The phosphatase activity, measured by the rate of
PNPP hydrolysis, is expressed as percent of the positive control (no
serum added).
doi:10.1371/journal.pone.0022081.g003
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2D-CD4 or the pre-formed CD4-gp120 complex. As shown in
Table 3, MAb DB81 bound 2D-CD4 with an affinity of 8.6 nM,
but the affinity increased approximately 800 times (9.6 pM) when
2D-CD4 was complexed with gp120 IIIB. From the binding
kinetics, it is evident that the main parameter responsible for this
change was not the association constant, which was quite high for
both ligands (,10
5 M-1s-1), but rather the dissociation constant
that was 2.7610
-3 s-1 for 2D-CD4 and 2.9610
-6 s-1 for the CD4-
gp120 complex. Notably, the affinity of MAb DB81 for FSLC was
roughly five times lower as compared to that for CD4, a results
that mainly resulted from a remarkably low on-rate, ,3 logs lower
than for CD4 and the complex, suggesting that the accessibility of
the DB81 epitope was impaired in this construct. In contrast, the
off-rate was quantitatively close to that of the CD4-gp120
complex, a result compatible with the structure of FSLC, which
is a mimetic of the CD4-gp120 complex.
Effect of MAb DB81 on HIV-1 Env-mediated fusion and
infection
Next, we examined the ability of MAb DB81 to block fusion
mediated by a panel of HIV-1 Envs derived from both laboratory
adapted and primary isolates. As shown in Figure 7A, MAb DB81
efficiently inhibited fusion mediated by the Env of three different
HIV-1 isolates with diverse coreceptor-usage phenotype, Ba-L
(R5), B117 (R5X4), IIIB (X4) and 6195 (R5X4). In these assays,
MAb DB81 showed a potency similar to that of Leu3A, a
reference anti-CD4 MAb directed against the gp120-binding site,
and RANTES, a CCR5 ligand (Fig. 7B). Taken together, these
results indicate that the DB81 epitope is accessible on the native
oligomeric gp120, and is conserved in CD4-Env complexes formed
by HIV-1 strains with different coreceptors-usage phenotype.
We also tested the ability of MAb DB81 to inhibit acute
infection by different laboratory-adapted and primary HIV-1
isolates in primary PBMC cultures. PHA-activated PBMC were
acutely infected with two laboratory-adapted isolates, IIIB (X4)
and Ba-L (R5), and two primary isolates, minimally passaged ex
vivo, 91US714 (R5) and 92US077 (R5X4). MAb DB81 was used to
pre-treat the cells before infection and then maintained at the
same concentration throughout the experiment. HIV-1 inhibition
was evaluated as reduction of extracellular p24 Gag antigen
production. The results, presented as half maximal inhibitory
concentrations (IC50), demonstrate a potent inhibitory activity of
MAb DB81 irrespective of the viral isolate tested (Fig. 7C).
Effects of MAb DB81 on antigen-induced T-cell
proliferation and complement fixation
Since a major concern with the potential clinical use of
antibodies directed against T cell-expressed antigens is the risk of
inducing immunosuppression, we evaluated the effects of MAb
DB81 on nominal antigen-induced T-cell proliferation. As shown
in Figure 8A, MAb DB81 did not exert inhibitory effects on the
proliferation of primary human PBMC stimulated with a nominal
antigen (tetanus toxoid) or with a polyclonal activator (PHA), while
the isotype-matched anti-CD4 MAb Leu3a displayed marked
suppressive effects. MAb DB81 was also poorly efficient in in-
ducing complement fixation and cytolysis, as measured by pro-
pidium iodide incorporation following exposure of MAb-treated
cells to rabbit complement; again, the isotype matched MAb
Leu3a displayed a markedly higher activity (Fig. 8B).
Sequence analysis of MAb DB81 genes
Both the light and heavy chains of the MAb DB81 gene were
sequenced. Analysis of the light chains by the international
ImMunoGeneTics information systemH(IMGT) [38] assigned the
V-gene to the IgK V6-17*01 gene family and the J-gene to the
IgK J2*01 gene family, with levels of identity of 97.8 and 88.2%,
respectively. The VK complementary determining region (CDR)
1, CDR2 and CDR3 lengths were 6, 3 and 9 amino acids,
respectively; the amino acid sequence in the junction encompass-
ing framework (FR) 3 and CDR3 was CQQHYSTPPTF. The
complete sequence of the light chain of MAb DB81 is available in
the EMBL database under accession number CAQ16368.
Analysis of the FR and CDR delimitations of the MAb DB81
light chain is shown in Table 4.
Analysis of the heavy chain of MAb DB81 assigned the V-gene
to the IgH V1-39*01 family and the J-gene to the IgH J3*01
family, with identity levels of 91.7 and 82.3%, respectively. The D-
gene was assigned to the IgH D2-2*01 family, in reading frame 3.
The VH CDR1, CDR2 and CDR3 lengths were 8, 8 and 12
amino acids, respectively; the amino acid sequence in the junction
Table 1. Characteristics of the IgG-secreting hybridomas
obtained from immunization of Balb-c mice with native HIV-1
Env complexed with sCD4.
Well no.
Binding
to CD4
Binding
to gp120
Binding to
CD4-gp120
A1 2.203 0.045 1.321
A2 2.342 0.035 1.221
A3 3.222 0.032 0.982
A9 0.040 2.121 2.001
A10 0.045 2.980 2.322
A11 0.034 1.342 1.032
A12 0.098 1.323 1.120
B4 0.043 0.430 0.462
B6 0.087 0.324 0.231
B6 0.087 0.342 0.231
B12 2.120 0.131 2.241
C1 1.320 0.011 1.232
C2 1.983 0.198 1.763
C3 1.348 0.022 1.134
C8* 1.221 0.045 1.430
C9* 1.234 0.023 1.998
C10* 1.432 0.042 1.743
C11* 1.565 0.079 2.211
C12* 0.092 1.211 1.243
D1 0.102 0.942 0.872
D2 0.023 1.234 1.356
D3 0.113 0.534 0.435
D10* 1.234 0.045 2.311
D11* 1.342 0.023 2.432
D12* 1.532 0.065 2.543
Binding activity to the indicated solid-phase antigens of IgG present in culture
supernatants from hybridomas derived from spleen cells of mice immunized
with NIH-3T3 cells infected with vaccinia recombinant vCB43, expressing Env
from the R5 HIV-1 isolate Ba-L, and complexed with 2-domain sCD4. Binding
activity was measured with culture supernatants diluted 1:1 (see methods).
Values are qualitative, since different microcultures contained different
numbers of cells. Asterisks indicate supernatants where an increased binding to
the 2D-CD4/gp120 (Ba-L) complex was observed as compared to the binding to
each moiety separately.
doi:10.1371/journal.pone.0022081.t001
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22081Figure 4. Membrane expression of the DB81 epitope. A. Cytofluorimetric analysis of MAb DB81 binding to RK13 cells expressing HIV-1 Ba-L
and treated or not with soluble CD4. A FITC-conjugated, affinity purified polyclonal antibody to mouse IgG was used as a secondary reagent. The blue
line shows background binding of the secondary antibody; the red line shows binding of MAb DB81 to untreated cells; the green line shows binding
of MAb DB81 to cells pre-treated with 2D-CD4. B. Cytofluorimetric analysis of MAb DB81 binding to RK13 cells expressing HIV-1 Ba-L and treated or
not with a CD4 miniprotein (CD4-M3). A FITC-conjugated, affinity purified polyclonal antibody to mouse IgG was used as a secondary reagent. The
blue line shows background binding of the secondary antibody; the red line shows binding of MAb DB81 to untreated cells; the green line shows
binding of MAb DB81 to cells pre-treated with CD4-M3. C, D. Cytofluorimetric analysis of MAb DB81 binding to PM-1 cells treated or not with HIV-1
gp120. A FITC-conjugated, affinity purified polyclonal antibody to mouse IgG was used as a secondary reagent. The blue line indicates background
binding of the secondary antibody; the red histogram shows binding of MAb DB81 to untreated PM-1 cells; the green histogram shows binding to
PM-1 cells pre-treated with recombinant gp120 Ba-L (C) or recombinant gp120 IIIB (D), respectively.
doi:10.1371/journal.pone.0022081.g004
Table 2. Sequence alignment of segment 126-204 from the second Ig-like domain of the CD4 molecule from different primate
species.
Species Sequence DB81 epitope
H. sapiens -TANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAF- yes
P. anubis -TANSDTHLLEGQSLTLTLESPPGTSPSVKCRSPRGKNIQGGRTL - - -------------NVSQDQKTVEFKIDIVVLAF- no
M. nemestrina -TANSDTHLLEGQSLTLTLESPPGSSPSVKCRSPGGKNIQGGRTLSVPQLERQDSGTWTCTVSQDQKTVEFKIDIVVLAF- no
P. troglodytes -TANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAF- yes
M. mulatta -TANSDTHLLEGQSLTLTLESPPGSSPSVKCRSPGGKNIQGGRTISVPQLERQDSGTWTCTVSQDQKTVEFKIDIVVLAF- no
M. fascicularis -TANSDTHLLEGQSLTLTLESPPGSSPSVKCRSPGGKNIQGGRTLSVPQLERQDSGTWTCTVSQDQKTVEFKIDIVVLAF- no
-*********:*************:**** **** *******:******** ********** * ** ************-
Sequences (amino-acids 126 to 204) were obtained from UniProt under the following accession numbers: Homo sapiens (P01730), Papio anubis (C1JYS8 and B1NC12),
Macaca nemestrina (Q08340), Pan troglodytes (P16004), Macaca mulatta (P16003), Macaca fascicularis (P79185). The underlined sequences indicate the two synthetic
peptides used for epitope mapping. Alignment was performed using the T-COFFEE software (version 1.41) and with the Nomad (Neighborhood Optimizationf o r
Multiple Alignment Discovery) program. Asterisks indicate identity; colons indicate homology. Positions with non-conservative substitutions between human and
nonhuman primate sequences are in bold.
doi:10.1371/journal.pone.0022081.t002
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complete sequence of the heavy chain of MAb DB81 is available
in the EMBL database under accession number CAQ16367.
Analysis of the FR and CDR delimitations of the MAb DB81
heavy chain is shown in Table 5.
Discussion
In this study, we used an unconventional approach to immunize
mice with the native, trimeric form of the HIV-1 Env complexed
with recombinant soluble 2D-CD4, thus presenting the activated,
fusion-competent conformation of Env. We succeeded in the
elicitation of antibodies that recognized, in addition to constitu-
tively expressed CD4-specific and Env-specific epitopes, a
repertoire of complex-enhanced epitopes whose expression was
functionally related to cell-fusion inhibition. A panel of MAbs was
generated from Env-CD4 complex-immunized mice, which
provided a useful tool for a more precise characterization of the
specificity of the antibody response elicited by this unconventional
immunization method. To our surprise, the MAbs that reacted
with complex-enhanced epitopes were not directed against the
gp120 moiety, as previously described for MAbs against CD4-
induced epitopes [11,36,37] but rather to the CD4 moiety.
Although we cannot exclude, in principle, the possibility that these
MAbs recognize ‘bridging’ epitopes encompassing both CD4 and
gp120, this hypothesis seems unlikely considering the complete
lack of reactivity against the isolated gp120 moiety as well as
against gp120 in its CD4-bound conformation induced by
interaction with a CD4 miniprotein. Importantly, most of the
elicited antibodies displayed HIV-1-neutralizing activity. Thus,
our experimental system seems to have favored the elicitation of
antibodies directed against CD4 epitopes that are conformation-
ally modified upon binding to gp120, a feature that was never
hitherto described for CD4. In fact, as we recently reported [39],
Figure 5. BIACOREH sensogram of interactions between MAb
DB81 (bound to the chip) and peptides GTWTCTVLQNQKKVEF-
KID (human, shown as a green line) or peptide GTWT-
CTVSQDQKTVEFKID (baboon, shown as a red line). The peptides
correspond to aa. 180-198 of membrane CD4 from Hominidae
(e.g., Homo and P. troglogites) and Cercopithecidae (e.g., Macaca),
respectively.
doi:10.1371/journal.pone.0022081.g005
Figure 6. BIACOREH sensogram of interactions between MAb DB81 (bound to the chip) and 2D-CD4 (light blue), gp120 IIIB (violet),
CD4-gp120 IIIB complex (green) or the FLSC chiimeric protein (dark blue).
doi:10.1371/journal.pone.0022081.g006
Table 3. Affinities and binding kinetics of MAb DB81.
Analyte Kd (610
-9 M) Kon (610
5 M
-1s
-1)K off (610
-3s
-1)
CD4 8.57 3.17 2.7
CD4 + gp120IIIB 0.0096 3.10 0.0029
FLSC 44.9 0.00231 0.01
Association (Kon) and dissociation (Koff) rate constants for purified MAb DB81
were measured by surface plasmon resonance. The Kd was calculated as
Koff\\Kon.
doi:10.1371/journal.pone.0022081.t003
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e22081comparison of the crystal structures of unbound and gp120-bound
human CD4 reveals widely overlapping tridimensional conforma-
tions, without major alterations induced upon ligation. However,
when C-a atom B-factors were considered as a measure of local
backbone mobility, the second CD4 domain (D2) displayed large
variations throughout its structure, whereas the first domain (D1)
did not display any significant variation with the exception of the
region that directly contacts gp120 [39]. This result suggests that
Figure 7. Inhibitory effect of MAb DB81 on HIV-1 Env-mediated fusion and infection. A. Effect of MAb DB81 on HIV-1 Env-mediated
fusion. Chronically infected PM-1 cells were used as effector cells. NIH 3T3 cells expressing CD4 and the appropriate coreceptor were used as target
cells. Fusion inhibition is expressed as percent of the fusion obtained with the untreated control (no antibody added). B. Comparison of the inhibitory
potency of MAb DB81 with that of other HIV-1 inhibitors. Comparison of fusion inhibition by MAb DB81 with that obtained with equimolar amounts
of another mAb to human CD4 (Leu3a) or the coreceptor inhibitor RANTES. PM-1 cells chronically infected with HIV-1 Ba-L were used as effectors. NIH
3T3 cells expressing the CCR5 coreceptor were used as targets. Results are expressed as percent of the fusion measured in the positive control (no
inhibitors added). C. Effect of MAb DB81 on HIV-1 infection in primary human PBMC. PBMC from healthy blood donors were infected with the
indicated HIV-1 strains in the presence or absence of MAb DB81. HIV-1 92US077 and 92US714 are two primary isolates derived directly from patient
blood cells and minimally passaged ex vivo exclusively in primary cells. HIV-1 replication was measured after 4 days by p24 ELISA and expressed as
percent of p24 measured in control untreated cultures. IC50 values were calculated using the PRISM software.
doi:10.1371/journal.pone.0022081.g007
Figure 8. Immunosuppressive and complement-fixing effects of MAb DB81. A. Inhibition of PBMC proliferation by MAb DB81. PBMC from 4
healthy blood donors were incubated with the indicated stimuli in a 5-day proliferation assay. Either no inhibitors (‘‘nil’’) or the indicated mAbs (3 mg/
ml) were added at the beginning of the culture time. Proliferation was measured by incorporation of tritiated thymidine in triplicate wells. The values
indicate the mean 6 standard error of the mean. B. Complement fixation by MAb DB81. Flow cytometry analysis of PM-1 cells treated with
complement only (C, top left) or with C plus thymoglobulin (polyclonal rabbit antibodies to human thymocyte antigens, ATG, bottom right), C plus
MAb Leu-3a (bottom left) or C plus DB81 (top right). Cells were stained with propidium iodide as a marker for cell death. Numbers in panels indicate
the percent of stained (complement lysed, dead) cells, which fell within the double arrow markers in the different experimental settings.
doi:10.1371/journal.pone.0022081.g008
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upon binding to gp120, whilst the D1 domain remains virtually
unaltered in its local mobility. This altered local mobility of D2
may influence the immunogenicity of CD4 by specifically exposing
or masking specific residues. Moreover, it has to be emphasized
that the existing crystal structures of the gp120-CD4 molecular
complex were obtained using drastically truncated and fully
deglycosylated gp120 core molecules, which might lack specific
sites involved in the interaction with CD4. Thus, it is possible that
CD4 undergoes more substantial conformational changes than it is
currently appreciated after binding to the full-length, native
gp120 molecule, which may have been missed due to the
limitations of the existing structural models of gp120. The lack
of previous reports of ‘‘gp120-induced’’ epitopes of CD4 may be a
consequence of the primary focus of most investigators on gp120-
specific epitopes or of the specific antigenic make-up of our
immunogens, in which a soluble form of CD4 was complexed with
the native, fully glycosylated, trimeric Env spike expressed on the
surface of mammalian cells. In principle, immunogens expressing
complex-specific epitopes on properly folded, membrane gp120
trimers are advantageous as compared to complexes formed with
recombinant soluble molecules [40,41]. In fact, the latter expose a
large array of epitopes from the ‘‘silent’’ face of gp120, which
remain embedded inside the core of the trimer in the native Env
spike, and therefore are inaccessible to antibodies [2,42]. For these
reasons, our approach may prove effective in eliciting antibodies
against conserved neutralization epitopes of potential relevance to
a protective anti-HIV-1 vaccine.
Table 4. Framework (FR) and Complementary Determining Region (CDR) delimitations of the light chain of MAb DB81: DB81 VK.
,-- --- --- --- --- --- --- --- --- --- --- FR1 - IMGT
1 5 10 15
DI V M T Q S H K F M S T S V
gac atc gtg atg acc cag tct cac aaa ttc atg tcc aca tca gta
--- --- --- --- --- --- --- --- --- --- --. ___ ___ ___ ___
20 25 30
G D RVSI TCKASQDVS
gga gac agg gtc agc atc acc tgc aag gcc agt cag gat cag agt
___ CDR1 - IMGT ___ ___ ___ ___ ,-- --- --- --- --- --- ---
35 40 45
TT VAW YQQK
act act ... ... ... ... ... ... gtg gcc tgg tat cag cag aaa
FR2 - IMGT --- --- --- --- --- --- --. ___ ___ ___ ___ CDR2
50 55 60
PGQ S P K L L I Y S A S
cca ggg caa tct cct aaa cta ctg att tat tcg gca tcc ... ...
- IMGT ___ ___ ___ ,-- --- --- --- --- --- --- --- --- ---
65 70 75
YRYTGVP DR
... ... ... ... ... tac cgg tac act gga gtc cct ... gat cgc
--- --- --- --- --- --- --- --- FR3 - IMGT --- --- --- ---
80 85 90
F T GSG SGTDFTFT
ttc act ggc agt gga ... ... tct ggg acg gat ttc act ttc acc
--- --- --- --- --- --- --- --- --- --- --- --- --- --. ___
95 100 104
I S SVQAEDLAVYYCQ
atc agc agt gtg cag gct gaa gac ctg gca gtt tat tac tgt cag
___ ___ CDR3 - IMGT ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
Q H YSTPPTFGGGTKL
caa cat tat agt act cct ccc acg ttc gga ggg ggc acc aag ctg
___ ___
EI R
aa ata cgg
doi:10.1371/journal.pone.0022081.t004
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be considered in the perspective of developing an effective vaccine
based on native HIV-1 Env-CD4 complexes. First, immunized
mice developed significant levels of anti-human CD4 antibodies.
Although in humans the induction of anti-self antibodies should be
restricted, this remains a concern for the risk of eliciting auto-
immune reactions. Moreover, the need to employ fixed cells
transduced with a recombinant vector for the expression of the
HIV-1 Env in the fully native trimeric conformation poses
additional safety concerns. Specifically, after repeated immuniza-
tions, we observed that tolerance to NIH 3T3 murine cells was
partially broken, and individual mice started to produce antibodies
to cellular antigens (not shown). Furthermore, the process of
validation of our immunogens before injection revealed that the
preparation of the vaccine was rather difficult to standardize, and
roughly one third of the batches that we prepared had to be
discarded before injection because they did not meet the quality
criteria that we had established. This may be due to several
reasons, including batch-to-batch differences in the expression of
Env by vaccinia-infected cells, internalization of Env-CD4 com-
plexes before fixation, or subtle changes in the fixation procedure
itself. Nevertheless, our results establish the proof-of-principle that
immunization with cell-surface-expressed native HIV-1 Env-CD4
complexes may be effective in eliciting the production of broadly
neutralizing antibodies against HIV-1 Env and/or CD4, opening
the way for further refinement of this vaccine approach.
One of the MAbs that we obtained from mice immunized
with CD4-complexed HIV-1 Env (DB81) was thoroughly
Table 5. Framework (FR) and Complementary Determining Region (CDR) delimitations of the heavy chain of MAb DB81: DB81 VH.
,-- --- --- --- --- --- --- --- --- --- --- --- FR1 - IMGT
1 5 10 15
E V QL QQSGP EL VKP
gaa gta cag ctg caa cag tct gga cct ... gaa ctg gtg aag cct
--- --- --- --- --- --- --- --- --- --- --. ___ ___ ___ ___
20 25 30
G A SVKI SCKASGYSF
ggg gct tca gtg aag ata tcc tgc aag gct tct ggt tat tca ttc
___ CDR1 - IMGT ___ ___ ___ ___ ,-- --- --- --- --- --- ---
35 40 45
TDY T M L W V K Q S
act gac tac acc ... ... ... ... atg ctc tgg gtg aag cag agc
FR2 - IMGT --- --- --- --- --- --- --. ___ ___ ___ ___ CDR2
50 55 60
HGK S L E W I G N I N P Y Y
cat gga aag agc ctt gag tgg att gga aat att aat cct tac tat
- IMGT ___ ___ ___ ,-- --- --- --- --- --- --- --- --- ---
65 70 75
DTT T Y N L N F K … G K
gat act act ... ... acc tac aat ctg aac ttc aag ... ggc aag
--- --- --- --- --- --- --- --- FR3 - IMGT --- --- --- ---
80 85 90
A T MT V DK S S S T AY MQ
gcc aca atg act gta gac aaa tct tcc agc aca gcc tac atg cag
--- --- --- --- --- --- --- --- --- --- --- --- --- --. ___
95 100 104
L N SLTSEDSAVYYCA
ctc aat agt ctg aca tct gag gac tct gca gtc tac tac tgt gca
___ ___ CDR3 - IMGT ___ ___ ___ ___ ___ ___ ___ ___ ___ ___
110 115 120
R E GDYGHPFAYW GQG
aga gag ggg gac tat ggt cac cct ttt gct tac tgg ggc caa ggg
___ ___ ___ ___ ___ ___ ___
125
T L VTVSS
act ctg gtc act gtc tcg agc
doi:10.1371/journal.pone.0022081.t005
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mapped to the outermost two domains of CD4 and more
specifically to the vicinity of a 13-aa. loop in domain 2 to which
none of the anti-CD4 MAbs so far reported seems to bind. In fact,
MAb DB81 did not compete for binding with any other CD4-
specific antibody tested. Of note, in contrast to previously reported
monoclonal antibodies raised from mice injected with soluble
CD4-gp120 complexes [43], MAb DB81 was reactive both with
the solid-phase and with the membrane-bound molecule By
plasmon resonance analysis, the binding affinity of DB81 to the
CD4-gp120 complex was almost one order of magnitude higher
than binding to the CD4 moiety alone. Moreover, the DB81
epitope was expressed on the FLSC peptide, a chimeric construct
designed to express in a stable form the set of conformational
epitopes that result from the post-binding reshaping of gp120 and
CD4 [28]. Interestingly, an anti-CD4 antibody which recognizes a
CD4 D2 epitope in proximity of the D1 CD4 domain (ibalizumab)
[44] was recently tested in phase II clinical trials, in the form of
humanized (IgG4) derivative, and appeared to be a promising tool
to block HIV-1 infection without inducing any immunologically
relevant side-effect either in vitro or in vivo [20,45]. Of note,
interference with conformational changes taking place at the post-
binding level was indicated as the likely mechanism of action also
for this antibody [46]. However, at variance with DB81,
ibalizumab does not seem to preferentially bind to CD4
complexed to gp120 [46].
Of importance in the perspective of a potential clinical use,
DB81 showed only a modest complement-fixation capability and
no interference with antigen-induced T-lymphocyte proliferation
in vitro. This limited immunosuppressive activity may be explained
by the relatively modest CD4-binding activity in the absence of
HIV-1 Env, or with the peculiar signaling that may be initiated via
binding to the DB81 epitope [47]. Notably, MAb DB81 induced
virtually no down-regulation of membrane CD4 on T lymphocytes
(not shown), unlike immunosuppressive anti-CD4 antibodies [48,
49]. Moreover, similarly to ibalizumab, the specificity of MAb
DB81 for the D2 domain of CD4 is also compatible with lack of
immune suppression, since CD4 interaction with major histocom-
patibility complex class II (MHC-II) is mediated by the D1 domain
[50]. These characteristics make DB81, or a derivative thereof, a
promising entry inhibitor that may be potentially useful either for
passive immunotherapy of HIV-1-infected individuals, or for early
post-exposure prevention of HIV-1 infection.
In conclusion, the present study supports the concept that a
vaccine based on native HIV-1 Env-CD4 molecular complexes
may elicit antibodies against partially cryptic neutralization epitopes
on both CD4 and gp120, which may have protective effects.
Moreover, a specific antibody generated with this approach may be
considered for the development of novel entry inhibitors for the
treatment or prevention of HIV-1 infection.
Supporting Information
Figure S1 Local conformation of the putative DB81 epitope in
the unliganded (green; accession code: 1WIP/MMDB 6042) and
gp120-bound (purple; accession code: 1G9N/MMDB 14984)
tridimensional structures of human CD4. The main chains are
depicted in the cartoon representation with arrows denoting beta-
strands; the insert shows the same region with the main chains
depicted as lines and the side chains as sticks. Small but significant
differences are seen in the positioning and length of the beta-
strands, as well as in the spatial orientation of the lateral chains,
which can justify the preferential reactivity of MAb DB81 with the
gp120-liganded form of CD4. In baboon and macaque CD4,
residues Leu162, Asn165 and Lys167 are substituted by Ser, Asp
and Thr, respectively.
(TIF)
Figure S2 Binding of MAb DB81 to solid phase CD4 or CD4-
gp120 complexes. Binding of MAb DB81 to solid phase 2D-sCD4,
either alone or in equimolar complex with different recombinant
gp120 (from isolates Ba-L or IIIB) was measured by ELISA.
(TIF)
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